Developing new treatments to target a protein linked to heart disease
Official title: Computational Development of Novel Dyslipidemia Therapeutic Candidates to Disrupt ApoC-III Conformation
Funded at Imetabolic Biopharma Corporation · NIH-10760187 · Data updated 2026-11-12
This study is looking at how a protein called ApoC-III affects heart health, especially for people who have high cardiovascular risk even when their LDL cholesterol is low, and the researchers are trying to find new treatments that can help clear this protein from the blood to improve heart health.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Imetabolic Biopharma Corporation NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $283,123 |
| NIH project number | 1R43HL170808-01 |
| Project ID | NIH-10760187 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with elevated triglyceride levels and a history of cardiovascular disease.
✕Less likely to help
Patients who have normal triglyceride levels and do not have cardiovascular risk factors may not benefit from this research.
What this research studies
This research focuses on cardiovascular disease, particularly the role of apolipoprotein C-III (ApoC-III) in maintaining high cardiovascular risk despite low levels of LDL cholesterol. The team at iMBP is using computational methods to design novel therapeutic candidates that can disrupt the harmful conformation of ApoC-III, which is known to inhibit important processes in lipid metabolism. By targeting this protein, the research aims to improve treatment options for patients who are at risk for cardiovascular events due to triglyceride-rich lipoprotein particles. The approach involves identifying compounds that can effectively alter the structure of ApoC-III to enhance its clearance from the bloodstream.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for reducing cardiovascular risk in patients with high levels of triglycerides.
How similar studies have gone: Previous research has shown promise in targeting ApoC-III for cardiovascular disease treatment, indicating that this approach could be a meaningful advancement.
Where this research is happening
-
Imetabolic Biopharma Corporation
Tempe, United States Active
Researchers
- Principal investigator: Kiernan, Urban a — Imetabolic Biopharma Corporation
- Study coordinator: Kiernan, Urban a
Related research
Other NIH-funded projects on the same topics.
-
Reducing harmful blood fats with a small sugar from human milk
This grant explores whether a human milk sugar called 3’SL can lower remnant cholesterol and inflammation to reduce heart disease risk in people with atherosclerosis.
-
Potential Effects of a Plasticizer on Dyslipidemia and Atherosclerosis
A study in young models looks at how certain plastic chemicals might influence cholesterol and artery disease through a key liver receptor.
-
Fabkin, a New Hormone Complex, and Its Role in Lipids and Inflammation Driving Atherosclerosis
A new hormone complex called Fabkin is being studied to see if it links fat metabolism and inflammation in atherosclerosis so future treatments could target both problems.
-
Diet-Driven Lipid Imbalance and Skin Inflammation Linked to Self-Lipid–Specific T Cells
This project looks at how diet-related changes in lipids may trigger immune cells that recognize self-lipids, potentially worsening skin inflammation in psoriasis.
-
Liver energy imbalance (NADH) and the driver ChREBP in fatty liver and high blood fats
This project aims to lower a liver chemical called NADH to see if that reduces liver fat and improves blood fat levels for people with alcoholic or non-alcoholic fatty liver disease.
-
Blood fats and diabetic eye disease
This project looks at how changes in certain fats in the blood and retina may cause or worsen diabetic retinopathy and whether targeting those fat pathways could help protect vision for people with diabetes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.